Chen Tao, Qiao Chenxiao, Yinwang Eloy, Wang Shengdong, Wen Xuehuan, Feng Yixuan, Jin Xiangang, Li Shuming, Xue Yucheng, Zhou Hao, Zhang Wenkan, Zeng Xianchang, Wang Zenan, Sun Hangxiang, Jiang Lifeng, Li Hengyuan, Li Binghao, Cai Zhijian, Ye Zhaoming, Lin Nong
Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
Orthopaedic Research Institute, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
J Immunother Cancer. 2024 Dec 4;12(12):e009629. doi: 10.1136/jitc-2024-009629.
Lung metastasis remains the primary cause of tumor-related mortality, with limited treatment options and unsatisfactory efficacy. In preclinical studies, T helper 9 (T9) cells have shown promise in treating solid tumors. However, it is unclear whether T9 cells can tackle more challenging situations, such as established lung metastases. Moreover, comprehensive exploration into the nuanced biological attributes of T9 cells is imperative to further unravel their therapeutic potential.
We adoptively transferred T1, T9, and T17 cells into subcutaneous, , and established lung metastases models of osteosarcoma and triple-negative breast cancer, respectively, comparing their therapeutic efficacy within each distinct model. We employed flow cytometry and an imaging system to evaluate the accumulation patterns of T1, T9, and T17 cells in the lungs after transfusion. We conducted bulk RNA sequencing on differentiated T9 cells to elucidate the chemokine receptor CXCR4, which governs their heightened pulmonary tropism relative to T1 and T17 cell counterparts. Using Cd4 Cxcr4 mice, we investigate the effects of CXCR4 on the lung tropism of T9 cells. We performed mass spectrometry to identify the E3 ligase responsible for CXCR4 ubiquitination and elucidated the mechanism governing CXCR4 expression within T9 cellular milieu. Ultimately, we analyzed the tumor immune composition after T9 cell transfusion and evaluated the therapeutic efficacy of adjunctive anti-programmed cell death protein-1 (PD-1) therapy in conjunction with T9 cells.
In this study, we provide evidence that T9 cells exhibit higher lung tropism than T1 and T17 cells, thereby exhibiting exceptional efficacy in combating established lung metastases. CXCR4-CXCL12 axis is responsible for lung tropism of T9 cells as ablating CXCR4 in CD4 T cells reverses their lung accumulation. Mechanistically, tumor necrosis factor receptor-associated factor 6 (TRAF6)-driven hyperactivation of NF-κB signaling in T9 cells inhibited ITCH-mediated ubiquitination of CXCR4, resulting in increased CXCR4 accumulation and enhanced lung tropism of T9 cells. Besides, T9 cells' transfusion significantly improved the immunosuppressed microenvironment. T9 cells and anti-PD-1 exhibit synergistic effects in tumor control.
Our findings emphasized the innate lung tropism of T9 cells driven by the activation of TRAF6, which supports the potential of T9 cells as a promising therapy for established lung metastases.
肺转移仍然是肿瘤相关死亡的主要原因,治疗选择有限且疗效不尽人意。在临床前研究中,辅助性T细胞9(T9)在实体瘤治疗方面显示出前景。然而,尚不清楚T9细胞是否能够应对更具挑战性的情况,如已形成的肺转移。此外,全面探究T9细胞细微的生物学特性对于进一步揭示其治疗潜力至关重要。
我们分别将T1、T9和T17细胞过继转移到骨肉瘤和三阴性乳腺癌的皮下、原位和已形成的肺转移模型中,比较它们在每个不同模型中的治疗效果。我们使用流式细胞术和成像系统评估输血后T1、T9和T17细胞在肺中的积累模式。我们对分化的T9细胞进行大量RNA测序,以阐明趋化因子受体CXCR4,其决定了T9细胞相对于T1和T17细胞更强的肺嗜性。使用Cd4 Cxcr4小鼠,我们研究CXCR4对T9细胞肺嗜性的影响。我们进行质谱分析以鉴定负责CXCR4泛素化的E3连接酶,并阐明T9细胞内环境中CXCR4表达的调控机制。最终,我们分析了T9细胞输血后的肿瘤免疫组成,并评估了辅助性抗程序性细胞死亡蛋白1(PD-1)疗法与T9细胞联合使用的治疗效果。
在本研究中,我们提供证据表明,T9细胞比T1和T17细胞表现出更高的肺嗜性,从而在对抗已形成的肺转移方面表现出卓越的疗效。CXCR4-CXCL12轴负责T9细胞的肺嗜性,因为在CD4 T细胞中消除CXCR4会逆转它们在肺中的积累。从机制上讲,肿瘤坏死因子受体相关因子6(TRAF6)驱动的T9细胞中NF-κB信号的过度激活抑制了ITCH介导的CXCR4泛素化,导致CXCR4积累增加和T9细胞的肺嗜性增强。此外,T9细胞的输血显著改善了免疫抑制微环境。T9细胞和抗PD-1在肿瘤控制方面表现出协同作用。
我们的研究结果强调了由TRAF6激活驱动的T9细胞固有的肺嗜性,这支持了T9细胞作为已形成肺转移的一种有前景的治疗方法的潜力。